CP-673451 is primarily utilized in biochemical research as a selective inhibitor of platelet-derived growth factor receptor (PDGFR) kinase. Its application is significant in studies focused on understanding cellular signaling pathways, particularly those involving PDGFR, which plays a crucial role in cell growth, proliferation, and differentiation. Researchers employ CP-673451 to investigate the effects of PDGFR inhibition in various cellular processes and disease models, including cancer, fibrosis, and atherosclerosis. By blocking PDGFR activity, this compound helps elucidate the receptor's role in tumor progression and vascular remodeling, providing insights that could lead to the development of targeted therapies. Additionally, CP-673451 is used in experimental settings to explore its potential in reducing pathological conditions associated with excessive PDGFR signaling, such as tissue scarring and abnormal blood vessel formation. Its specificity and potency make it a valuable tool in preclinical studies aimed at identifying novel therapeutic strategies for diseases driven by PDGFR dysregulation.